Monoclonal antibodyPhase 3 trialInvestigational
Ramucirumab
How it works
Blocks the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting tumor angiogenesis.
Cancer types
Colorectal Cancer— All patients
Lung Cancer— All patients
Efficacy
In clinical trials, Ramucirumab in combination with chemotherapy improved median overall survival by approximately 1.4 months compared to chemotherapy alone.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.